Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors - PubMed (original) (raw)
. 2009 Oct;20(10):1674-81.
doi: 10.1093/annonc/mdp060. Epub 2009 Jun 23.
F A Shepherd, J-Y Douillard, J Wolf, G Giaccone, L Crino, F Cappuzzo, S Sharma, S H Gross, S Dimitrijevic, L Di Scala, H Gardner, L Nogova, V Papadimitrakopoulou
Affiliations
- PMID: 19549709
- DOI: 10.1093/annonc/mdp060
Free article
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
J-C Soria et al. Ann Oncol. 2009 Oct.
Free article
Abstract
Background: Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients. RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
Methods: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing.
Results: Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum. ORR was 4.7% (7.1% stratum 1; 2.3% stratum 2). Overall disease control rate was 47.1%. Median progression-free survivals (PFSs) were 2.6 (stratum 1) and 2.7 months (stratum 2). Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS.
Conclusions: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC. Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.
Similar articles
- Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. Price KA, et al. J Thorac Oncol. 2010 Oct;5(10):1623-9. doi: 10.1097/JTO.0b013e3181ec1531. J Thorac Oncol. 2010. PMID: 20871262 Free PMC article. Clinical Trial. - Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Papadimitrakopoulou VA, et al. J Thorac Oncol. 2012 Oct;7(10):1594-601. doi: 10.1097/JTO.0b013e3182614835. J Thorac Oncol. 2012. PMID: 22968184 Clinical Trial. - Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. White DA, et al. J Thorac Oncol. 2009 Nov;4(11):1357-63. doi: 10.1097/JTO.0b013e3181ba20b1. J Thorac Oncol. 2009. PMID: 19745764 Clinical Trial. - [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y, Huang ZY, Yu HF, Luo LH. Fan Y, et al. Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21223694 Clinical Trial. Chinese. - Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Johnson BE, Jackman D, Jänne PA. Johnson BE, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31. doi: 10.1158/1078-0432.CCR-07-0717. Clin Cancer Res. 2007. PMID: 17671154 Review.
Cited by
- MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. Casacuberta-Serra S, et al. Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z. Signal Transduct Target Ther. 2024. PMID: 39164274 Free PMC article. Review. - Recent advances in non-small cell lung cancer targeted therapy; an update review.
Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Araghi M, et al. Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review. - The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis.
Qiu W, Ren M, Wang C, Fu Y, Liu Y. Qiu W, et al. Medicine (Baltimore). 2022 Dec 23;101(51):e32340. doi: 10.1097/MD.0000000000032340. Medicine (Baltimore). 2022. PMID: 36595789 Free PMC article. - Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16).
Byeon S, Kang MJ, Choi YJ, Kim YJ, Kim M, Yun J, Yi SY, Kim JY, Kim ST, Lee J. Byeon S, et al. Transl Cancer Res. 2020 May;9(5):3222-3230. doi: 10.21037/tcr.2020.04.07. Transl Cancer Res. 2020. PMID: 35117688 Free PMC article. - Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development.
Samarelli AV, Masciale V, Aramini B, Coló GP, Tonelli R, Marchioni A, Bruzzi G, Gozzi F, Andrisani D, Castaniere I, Manicardi L, Moretti A, Tabbì L, Guaitoli G, Cerri S, Dominici M, Clini E. Samarelli AV, et al. Int J Mol Sci. 2021 Nov 10;22(22):12179. doi: 10.3390/ijms222212179. Int J Mol Sci. 2021. PMID: 34830058 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous